Method of ameliorating herpes simplex virus infections using purified nerve growth factor
US5232695A · kind A · utility
4Cited by
2References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 6, 1990 |
| Grant date | Aug 3, 1993 |
| Priority date | — |
| Expiry date | Dec 6, 2010 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/185
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of treatment are described for use of purified nerve growth factor to ameliorate viral infections in an animal caused by Herpes Simplex Virus Types 1 and 2. Compositions are described for use in the treatment comprising purified nerve growth factor alone or in conjunction with a Herpes Simplex Viral antiviral agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.